incidence of cancers among children living with hiv in malawi after widespread availability of antiretroviral therapy a population based study

Original title: “Incidence of Cancers Among Children Living With HIV in Malawi After Widespread Availability of Antiretroviral Therapy: A Population-Based Study.”

esophageal cancer in somalia burden and outcomes from a multicenter observational study in mogadishu

Original title: “Esophageal Cancer in Somalia: Burden and Outcomes From a Multicenter Observational Study in Mogadishu.”

Generate’s performance came on a day in which the broader financial markets plummeted on news of a higher-than-expected increase during January in the “core” producer price index (PPI) which excludes food and energy prices. Generate carried out the largest biotech IPO so far this year, saying that proceeds from the offering will be used toward clinical trials, as well as platform and pipeline R&D efforts. [Nasdaq] Generate:Biomedicines aims to build on pipeline now focused on cancer, I&I candidates, with plans to use proceeds toward funding clinical trials, platform and therapy R&D GEN – Genetic Engineering and Biotechnology News ... [Front row, center:] Generate: Biomedicines CEO Michael Nally and Jason Silvers, MD, JD, president and chief financial officer, lead a team of employees in celebrating the artificial intelligence (AI)-based platform and drug developer’s $400 million initial public offering (IPO) Friday on the Nasdaq Global Market. Generate:Biomedicines (NASDAQ: GENB), the drug developer focused on creating immunology and inflammation (I&I) and oncology treatments through its own artificial intelligence (AI)-based platform, has launched the year’s largest biotech initial public offering (IPO) to date, raising $400 million in gross proceeds toward clinical trials, as well as platform and pipeline R&D efforts. Among the next two highest biotech IPOs, late-stage oncology and neuroscience drug developer Eikon Therapeutics (NASDAQ: EIKN) raised $381 million gross proceeds priced on February 4, while radiopharma drug developer Aktis Oncology (NASDAQ: AKTS) racked up $318 million in gross proceeds priced on January 8.

Original title: “StockWatch: AI Drug Developer Generates $400M IPO”

Has living with the uncertainty of this rare syndrome changed her? She talks about how some people say having cancer is a blessing, which she understands. “I think I am a strong introverted woman who has the ability to be extroverted when needed, I can speak for those voices who need my help, I can hold a person’s hand through their last breath, I can sit at a table to discuss the needs of patients,” she says of the support and advocacy ... Has living with the uncertainty of this rare syndrome changed her? She talks about how some people say having cancer is a blessing, which she understands. “I think I am a strong introverted woman who has the ability to be extroverted when needed, I can speak for those voices who need my help, I can hold a person’s hand through their last breath, I can sit at a table to discuss the needs of patients,” she says of the support and advocacy she’s devoted her days to. Sign up for patient and caregiver stories, expert insights, and advocacy for better access—delivered straight to your inbox. Anne Marie is a former realtor who is busier than ever in her retirement working with the organization. “There’s always something new to learn with this. I learn from my patients, from the doctors. That’s all good because that way it keeps me ahead of what’s out there.” · Rare Disease Day on Feb. You’re always having to explain yourself, your symptoms and what the disease actually means when you’re asked—or you try to avoid questions about your health. You might be confronted by a sheer lack of empathy, only out of ignorance. It’s not because people beyond your inner circle don’t care; they just don’t understand or want to take time to listen and learn. Rare diseases typically don’t make headlines or receive significant research dollars simply because they are rare and touch very few people.

Original title: “Rare Disease Day 2026: Finding purpose and community despite the odds | Healthing.ca”

Generate Biomedicines priced a $400M IPO at $16/share. Despite an asthma lead program, investors are watching the platform’s oncology reach. The IPO is a real-time signal about what public-market investors are currently willing to fund: platform narratives that claim to compress discovery timelines and generate multiple modalities, including assets relevant to cancer. At the same time, IPO coverage has highlighted a key diligence issue for AI-centric biotech valuations: industry observers still point out that a fully AI-discovered drug has not yet achieved U.S. Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under the ticker “GENB.” In February 2026, the offering was described as the largest biotechnology IPO to date for the year and part of an unusually active month for biotech listings. In addition to IPO proceeds, industry reporting cited more than $800 million in prior venture financing and approximately $110 million in collaboration payments from Amgen and Novartis tied to the company’s platform.

Original title: “Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus - OncoDaily”

Learn how to lower your cancer risk and what CDC is doing to prevent and control cancer.

Original title: “Cancer”

The Denton site is part of a network of manufacturing plants Novartis is building across the U.S. to make cancer drugs that must be shipped to patients quickly.

Original title: “Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility”

CDC offers resources about cancer in a variety of formats.

Original title: “Resource Library”

Billions of dollars’ worth of cancer drugs are discarded each year. Manufacturers must refund Medicare for some of this waste. A data-driven approach offers a practical path to greater efficiency.

Original title: “Cut Down on Oncology Drug Waste With Better Forecasting”

Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.

Original title: “Merck’s Keytruda Likely Has a Few Extra Years of Dominance, With Billions on the Line”

coexistence of friedreich s ataxia and esophageal cancer a case report

Original title: “Coexistence of Friedreich's Ataxia and Esophageal Cancer: A Case Report.”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled The National Firefighter Registry for Cancer (NFR). In accordance with the Firefight

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

Original title: “Merck to split cancer, specialty drug businesses in leadership shakeup”

Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.

Original title: “Grail’s multi-cancer early detection test misses study goal”

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. | Gilead penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. Gilead penned a $1.5 billion cancer deal. A cell therapy firm could end a biotech IPO drought in Tokyo. Novo faces more GLP-1 competition in China. Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased GLP-1 competition in China. Japanese cell therapy company Innovacell aims to go public on the Tokyo Stock Exchange on Feb. 24. With a regenerative therapy for urge fecal incontinence in phase 3 development, the company plans to initially offer 8.4 million shares at a price of 1,350 Japanese yen apiece. There were no biotech IPOs on Tokyo's stock exchange last year. 2. Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering

Original title: “Fierce Pharma Asia—Gilead's synthetic lethality deal; A Tokyo biotech IPO; Novo’s Ozempic China sales dip”

therapeutic vaccination for active induction of t cell immunity against cancer ready for a rich harvest after 40 years

Original title: “Therapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years.”

Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.

Original title: “Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand”

Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.

Original title: “Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs”

priority european strategies for sustainable access to high quality genetic counselling in cancer a delphi study

Original title: “Priority European strategies for sustainable access to high-quality genetic counselling in cancer: A Delphi study.”

A follow-up analysis of a clinical trial that evaluated anti-PD-1 therapy in patients with cancer who are living with HIV provides mechanistic insights into transcriptomic, cellular and cytokine changes related to immune checkpoint inhibitor treatment and identifies a signature associated with ... A follow-up analysis of a clinical trial that evaluated anti-PD-1 therapy in patients with cancer who are living with HIV provides mechanistic insights into transcriptomic, cellular and cytokine changes related to immune checkpoint inhibitor treatment and identifies a signature associated with clinical response. Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. Nature Medicine - A follow-up analysis of a clinical trial that evaluated anti-PD-1 therapy in patients with cancer who are living with HIV provides mechanistic insights into transcriptomic,... We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1–2 and objective antitumor response observed in five participants (one complete response and four partial responses). Within 24 hours of treatment, we observed an expansion of proliferating HIV-specific effector CD8+ T cells and a decline in plasma TGFβ.

Original title: “Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy | Nature Medicine”